164 related articles for article (PubMed ID: 1502011)
21. Metabolism of valproic acid by hepatic microsomal cytochrome P-450.
Prickett KS; Baillie TA
Biochem Biophys Res Commun; 1984 Aug; 122(3):1166-73. PubMed ID: 6433908
[TBL] [Abstract][Full Text] [Related]
22. Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids.
Silva MF; Ruiter JP; IJlst L; Jakobs C; Duran M; de Almeida IT; Wanders RJ
Chem Biol Interact; 2001 Sep; 137(3):203-12. PubMed ID: 11566289
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes.
Natarajan SK; Eapen CE; Pullimood AB; Balasubramanian KA
J Gastroenterol Hepatol; 2006 Aug; 21(8):1240-9. PubMed ID: 16872304
[TBL] [Abstract][Full Text] [Related]
24. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
[TBL] [Abstract][Full Text] [Related]
25. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies.
Kesterson JW; Granneman GR; Machinist JM
Hepatology; 1984; 4(6):1143-52. PubMed ID: 6437960
[TBL] [Abstract][Full Text] [Related]
26. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. III. Influence of fasting.
Löscher W; Wahnschaffe U; Hönack D; Drews E; Nau H
Epilepsy Res; 1993 Dec; 16(3):183-94. PubMed ID: 8119269
[TBL] [Abstract][Full Text] [Related]
27. Valproate-associated hepatotoxicity and its biochemical mechanisms.
Eadie MJ; Hooper WD; Dickinson RG
Med Toxicol Adverse Drug Exp; 1988; 3(2):85-106. PubMed ID: 3131628
[TBL] [Abstract][Full Text] [Related]
28. Valproate and mitochondria.
Ponchaut S; Veitch K
Biochem Pharmacol; 1993 Jul; 46(2):199-204. PubMed ID: 8347141
[No Abstract] [Full Text] [Related]
29. In vitro effects of eight-carbon fatty acids on oxidations in rat liver mitochondria.
Veitch K; Van Hoof F
Biochem Pharmacol; 1990 Nov; 40(9):2153-9. PubMed ID: 2242043
[TBL] [Abstract][Full Text] [Related]
30. Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes.
Aires CC; Soveral G; Luís PB; ten Brink HJ; de Almeida IT; Duran M; Wanders RJ; Silva MF
FEBS Lett; 2008 Oct; 582(23-24):3359-66. PubMed ID: 18775709
[TBL] [Abstract][Full Text] [Related]
31. Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria.
Silva MF; Ijlst L; Allers P; Jakobs C; Duran M; de Almeida IT; Wanders RJ
Drug Metab Dispos; 2004 Nov; 32(11):1304-10. PubMed ID: 15483197
[TBL] [Abstract][Full Text] [Related]
32. In vitro studies to elucidate the metabolic pathway of (+)-S-145, a thromboxane A2 receptor antagonist, in rats. Evidence for two independent pathways in peroxisomal beta-oxidation.
Yamaguchi Y; Baba T; Touchi A; Matsubara T
Drug Metab Dispos; 1995 Nov; 23(11):1195-201. PubMed ID: 8591718
[TBL] [Abstract][Full Text] [Related]
33. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.
Silva MF; Aires CC; Luis PB; Ruiter JP; IJlst L; Duran M; Wanders RJ; Tavares de Almeida I
J Inherit Metab Dis; 2008 Apr; 31(2):205-16. PubMed ID: 18392741
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations.
Kassahun K; Baillie TA
Drug Metab Dispos; 1993; 21(2):242-8. PubMed ID: 8097692
[TBL] [Abstract][Full Text] [Related]
35. Enantioselective synthesis and preliminary metabolic studies of the optical isomers of 2-n-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproic acid.
Porubek DJ; Barnes H; Theodore LJ; Baillie TA
Chem Res Toxicol; 1988; 1(6):343-8. PubMed ID: 2979751
[TBL] [Abstract][Full Text] [Related]
36. Formulations of valproate alter valproate metabolism: a single oral dose kinetic study.
Nagai G; Ono S; Yasui-Furukori N; Nakamura A; Mihara K; Kondo T
Ther Drug Monit; 2009 Oct; 31(5):592-6. PubMed ID: 19704403
[TBL] [Abstract][Full Text] [Related]
37. Valproyl-CoA and esterified valproic acid are not found in brains of rats treated with valproic acid, but the brain concentrations of CoA and acetyl-CoA are altered.
Deutsch J; Rapoport SI; Rosenberger TA
Neurochem Res; 2003 Jun; 28(6):861-6. PubMed ID: 12718439
[TBL] [Abstract][Full Text] [Related]
38. Co-cultures of rat hepatocytes in the study of valproate toxicity.
Rogiers V; Akrawi M; Vandenberghe Y; Shephard E; Phillips I; Vercruysse A
Arch Toxicol Suppl; 1992; 15():156-9. PubMed ID: 1510583
[No Abstract] [Full Text] [Related]
39. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines.
Fromenty B; Pessayre D
J Hepatol; 1997; 26 Suppl 2():43-53. PubMed ID: 9204409
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of zone-specific hepatic steatosis caused by valproate: inhibition of ketogenesis in periportal regions of the liver lobule.
Olson MJ; Handler JA; Thurman RG
Mol Pharmacol; 1986 Dec; 30(6):520-5. PubMed ID: 3097499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
